First, their strategy was based on the use of autologous DCs pulsed with tumor lysates, and we used allogenic DCs electrofused with living autologous tumor cells; second, in Liau et al.’s study, patients were enrolled during first-line treatment, just after surgery and radiotherapy, and 64 patients crossed over to DC vaccination after recurrence (as opposed to our study, which included only recurrent cases); third, Liau et al.’s patients were stratified according to MGMT status, and no IDH-status was presented. Here, MGMT is linked to neoplasm.